Human Genome Epidemiology Literature Finder
|
Records 1 - 17 (of 17 Records) |
| Query Trace: Breast Neoplasms and BID[original query] |
|---|
| Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 May 18 (5): 1610-6. Gaudet Mia M, Milne Roger L, Cox Angela, Camp Nicola J, Goode Ellen L, Humphreys Manjeet K, Dunning Alison M, Morrison Jonathan, Giles Graham G, Severi Gianluca, Baglietto Laura, English Dallas R, Couch Fergus J, Olson Janet E, Wang Xianshu, Chang-Claude Jenny, Flesch-Janys Dieter, Abbas Sascha, Salazar Ramona, Mannermaa Arto, Kataja Vesa, Kosma Veli-Matti, Lindblom Annika, Margolin Sara, Heikkinen Tuomas, Kämpjärvi Kati, Aaltonen Kirsimari, Nevanlinna Heli, Bogdanova Natalia, Coinac Irina, Schürmann Peter, Dörk Thilo, Bartram Claus R, Schmutzler Rita K, Tchatchou Sandrine, Burwinkel Barbara, Brauch Hiltrud, Torres Diana, Hamann Ute, Justenhoven Christina, Ribas Gloria, Arias José I, Benitez Javier, Bojesen Stig E, Nordestgaard Børge G, Flyger Henrik L, Peto Julian, Fletcher Olivia, Johnson Nichola, Dos Santos Silva Isabel, Fasching Peter A, Beckmann Matthias W, Strick Reiner, Ekici Arif B, Broeks Annegien, Schmidt Marjanka K, van Leeuwen Flora E, Van't Veer Laura J, Southey Melissa C, Hopper John L, Apicella Carmel, Haiman Christopher A, Henderson Brian E, Le Marchand Loic, Kolonel Laurence N, Kristensen Vessela, Grenaker Alnaes Grethe, Hunter David J, Kraft Peter, Cox David G, Hankinson Susan E, Seynaeve Caroline, Vreeswijk Maaike P G, Tollenaar Rob A E M, Devilee Peter, Chanock Stephen, Lissowska Jolanta, Brinton Louise, Peplonska Beata, Czene Kamila, Hall Per, Li Yuqing, Liu Jianjun, Balasubramanian Sabapathy, Rafii Saeed, Reed Malcolm W R, Pooley Karen A, Conroy Don, Baynes Caroline, Kang Daehee, Yoo Keun-Young, Noh Dong-Young, Ahn Sei-Hyun, Shen Chen-Yang, Wang Hui-Chun, Yu Jyh-Cherng, Wu Pei-Ei, Anton-Culver Hoda, Ziogoas Argyrios, Egan Kathleen, Newcomb Polly, Titus-Ernstoff Linda, Trentham Dietz Amy, Sigurdson Alice J, Alexander Bruce H, Bhatti Parveen, Allen-Brady Kristina, Cannon-Albright Lisa A, Wong Jathine, , Chenevix-Trench Georgia, Spurdle Amanda B, Beesley Jonathan, Pharoah Paul D P, Easton Doug F, Garcia-Closas Montserrat, |
| Distribution of coding apoptotic gene polymorphisms in women with extreme phenotypes of breast cancer predisposition and tolerance. Tumori 0 97 (2): 248-51. Ulybina Yulia M, Kuligina Ekatherina S, Mitiushkina Nathalia V, Sherina Nathalia Y, Baholdin Dmitry V, Voskresenskiy Dmitry A, Polyakov Igor S, Togo Alexandr V, Semiglazov Vladimir F, Imyanitov Evgeny |
| Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical breast cancer 2017 9 18 (1): e135-e142. Anampa Jesus, Chen Alice, Wright John, Patel Margi, Pellegrino Christine, Fehn Karen, Sparano Joseph A, Andreopoulou Ele |
| Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study. Cancer chemotherapy and pharmacology 2017 Mar . Tandia Mahamadou, Mhiri Asma, Paule Bernard, Saffroy Raphaël, Cailliez Valérie, Noé Gaëlle, Farinotti Robert, Bonhomme-Faivre Lauren |
| Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancer. Oncotarget 2017 Oct 8 (45): 79175-79187. Lee Jung-Min, Hays John L, Chiou Victoria L, Annunziata Christina M, Swisher Elizabeth M, Harrell Maria I, Yu Minshu, Gordon Nicolas, Sissung Tristan M, Ji Jiuping, Figg William D, Minasian Lori, Lipkowitz Stanley, Wood Bradford J, Doroshow James, Kohn Elise |
| Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer medicine 2018 May . Werner Theresa L, Sachdev Jasgit, Swisher Elizabeth M, Gutierrez Martin, Kittaneh Muaiad, Stein Mark N, Xiong Hao, Dunbar Martin, Sullivan Danielle, Komarnitsky Philip, McKee Mark, Tan Antoinette |
| Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients. Clinical pharmacology and therapeutics 2018 12 105 (6): 1492-1500. Zhou Diansong, Li Jianguo, Learoyd Maria, Bui Khanh, Berges Alienor, Milenkova Tsveta, Al-Huniti Nidal, Tomkinson Helen, Xu Hongm |
| Exposure-response analysis to inform the optimal dose of veliparib in combination with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer patients. Cancer chemotherapy and pharmacology 2019 Aug . Nuthalapati Silpa, Stodtmann Sven, Shepherd Stacie Peacock, Ratajczak Christine K, Mensing Sven, Menon Rajeev, Xiong H |
| Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI). American journal of clinical oncology 2019 Apr . Ahmed Faisal, Christos Paul J, Singh Prabhsimranjot, Parashar Bhupesh, Wernicke Alla Gabriel |
| Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 2019 12 11 (12): . Schneeweiss Andreas, Hess Dagmar, Joerger Markus, Varga Andrea, Moulder Stacy, Tsimberidou Apostolia M, Ma Cynthia, Hurvitz Sara A, Rentzsch Christine, Rudolph Marion, Thiele Silke, Boix Oliver, Wilkinson Gary, Lagkadinou Eleni, Ocker Matthi |
| Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Investigational new drugs 2019 10 38 (4): 1096-1107. van der Noll Ruud, Jager Agnes, Ang Joo Ern, Marchetti Serena, Mergui-Roelvink Marja W J, de Bono Johann S, Lolkema Martijn P, de Jonge Maja J A, van der Biessen Diane A, Brunetto Andre T, Arkenau Hendrik-Tobias, Tchakov Ilian, Beijnen Jos H, De Grève Jacques, Schellens Jan H |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2019 1 30 (4): 558-566. Robson M E, Tung N, Conte P, Im S-A, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek S |
| Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors. Chinese journal of cancer research = Chung-kuo yen cheng yen chiu 2020 Jun 32 (3): 370-382. Li Huiping, Liu Rongrui, Shao Bin, Ran Ran, Song Guohong, Wang Ke, Shi Yehui, Liu Jihong, Hu Wenjing, Chen Fu, Liu Xiaoran, Zhang Gairong, Zhao Chuanhua, Jia Ru, Wang Quanren, Rugo Hope S, Zhang Yifan, Li Guangze, Xu Jianmi |
| Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. Cancer chemotherapy and pharmacology 2020 2 85 (4): 741-751. Pothuri Bhavana, Brodsky Allison L, Sparano Joseph A, Blank Stephanie V, Kim Mimi, Hershman Dawn L, Tiersten Amy, Kiesel Brian F, Beumer Jan H, Liebes Leonard, Muggia Fran |
| A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
| Abemaciclib plus fulvestrant for the treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer with cystic brain metastases: A case report and literature review. Frontiers in oncology 2022 12 12 984454. Chu Zhaoh |
| OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European journal of cancer (Oxford, England : 1990) 2023 3 184 39-47. Robson Mark E, Im Seock-Ah, Senkus Elzbieta, Xu Binghe, Domchek Susan M, Masuda Norikazu, Delaloge Suzette, Tung Nadine, Armstrong Anne, Dymond Mike, Fielding Anitra, Allen Allison, Conte Pierfran |
- Page last reviewed:Feb 1, 2024
- Content source: